Injective CEO Meets White House, SEC and CFTC Officials as INJ Token Jumps Roughly 27%

Injective CEO Eric Chen met officials from the White House, the Securities and Exchange Commission and the Commodity Futures Trading Commission in Washington on Wednesday, Oct. 14. Injective said so on X the next day. Chen was joined by the company's General Counsel, Head of Policy and Head of Research.

The agenda, per Injective, was tokenization and onchain finance inside U.S. regulatory frameworks. The company has not said what officials told them. It has announced no approvals, rulings or commitments from the meetings.

What Injective brought to the table

The company arrived with a short regulatory résumé, all of it self-reported.

Injective says its unit, Injective Institutional Services, became an SEC-registered transfer agent in August 2026. Transfer agents keep the official records of who owns a security. That status would let Injective maintain ownership records for tokenized securities.

Injective also says INJ futures are listed on CFTC-regulated U.S. markets. It claims more than $1 billion in tokenized real-world asset value onchain and more than $5.3 billion in cumulative volume in perpetual contracts tied to assets such as equities and commodities. Those numbers come from the company.

In 2025, Injective proposed a time-based exemption for decentralized finance projects. The idea was to give early-stage protocols a window to develop before the full weight of securities rules applied. In September 2026, the SEC introduced its Innovation Exemption, a separate regulatory move. Injective has not claimed the SEC adopted its proposal.

The price move

INJ jumped between 23% and 30% over roughly 24 hours around Oct. 15 and 16. According to CoinGecko data, it reached almost $9.20 on Oct. 16, its highest level since October 2025. Its market capitalization rose above $920 million, which made it the 85th-largest cryptocurrency, ahead of Pi Network.

That is still far below the token's March 2024 peak of $52.75, per CoinMarketCap. At about $9, INJ sits roughly 83% under that high.

What drove the rally is disputed. CryptoPotato tied the move mainly to the Washington meeting. Crypto Briefing pointed instead to ETF filings. Around Sept. 18, 2026, 21Shares amended its filing for an Injective ETF that would hold INJ directly and allow discretionary staking. It is seeking a Nasdaq listing under the ticker TINJ. Canary Capital and REX-Osprey have also advanced filings for staked INJ ETF products.

CoinGecko listed another possible catalyst: a stakers' vote on IIP-709, a proposal for fixed gas fees.

Invezz, which covered the rally, said the attention around the policy talks "does not establish that the meetings caused the price recovery." Santiment data showed INJ's social dominance at 1.1% on Friday, Oct. 16, up from earlier levels. Santiment also showed INJ held on exchanges falling from about 1.26 million tokens to 872,500 since August.

Analysts see more upside

Analyst Ali Martinez said the rally "has just begun." He argued INJ broke out of a cup-and-handle chart pattern and projected a target near $14. Another analyst, MikybullCrypto, has forecast a run to $80 on a different chart pattern.

Those are price predictions from traders, not findings from any regulator. Technical-pattern targets have no official standing, and the same pages carry risk warnings that digital assets can lose all their value.

What a meeting does and does not mean

Meeting with the SEC, CFTC and White House staff is routine for crypto companies seeking clearer rules. Such meetings are not endorsements. Injective has shown no approval, no no-action letter and no public statement from any of the three bodies tied to the Oct. 14 talks.

The company's own timeline is a policy proposal in 2025, transfer agent registration in August 2026, regulated futures, and now direct access in Washington. Whether that adds up to a rule change that benefits tokenized assets is unresolved.

Clear, written rules for tokenized securities would serve companies and customers better than case-by-case negotiation. Until such rules exist, Injective's regulatory claims rest on its own announcements.

The next checkpoints are concrete. The SEC has to act on the pending ETF filings from 21Shares, Canary Capital and REX-Osprey, and Injective stakers have the IIP-709 fixed-gas-fee vote. Whether the Washington meetings produce any formal outcome is up to Injective to disclose.